In Black South Africans from Rural and Urban Communities, the 4G/5G PAI-1 Polymorphism Influences PAI-1 Activity, but Not Plasma Clot Lysis Time

Zelda de Lange1, Dingeman C. Rijken2, Tiny Hoekstra1,3, Karin R. Conradie1, Johann C. Jerling1, Marliien Pieters1*

1 Centre of Excellence for Nutrition, North-West University, Potchefstroom, South Africa, 2 Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands, 3 Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands

Abstract

Data on genetic and environmental factors influencing PAI-1 levels and their consequent effect on clot lysis in black African populations are limited. We identified polymorphisms in the promoter area of the PAI-1 gene and determined their influence on PAI-1 act levels and plasma clot lysis time (CLT). We also describe gene-environment interactions and the effect of urbanisation. Data from 2010 apparently healthy urban and rural black participants from the South African arm of the PURE study were cross-sectionally analysed. The 5G allele frequency of the 4G/5G polymorphism was 0.85. PAI-1 act increased across genotypes in the urban subgroup (p = 0.009) but not significantly in the rural subgroup, while CLT did not differ across genotypes. Significant interaction terms were found between the 4G/5G polymorphism and BMI, waist circumference and triglycerides in determining PAI-1 act and between the 4G/5G polymorphism and fibrinogen and fibrinogen gamma prime in determining CLT. The C428T and G429A polymorphisms did not show direct relationships with PAI-1 act or CLT but they did influence the association of other environmental factors with PAI-1 act and CLT. Several of these interactions differed significantly between rural and urban subgroups, particularly in individuals harbouring the mutant alleles. In conclusion, although the 4G/5G polymorphism significantly affected PAI-1 act, it contributed less than 1% to the PAI-1 act variance. (Central) obesity was the biggest contributor to PAI-1 act variance (12.5%). Urbanisation significantly influenced the effect of the 4G/5G polymorphism on PAI-1 act as well as gene-environment interactions for the C428T and G429A genotypes in determining PAI-1 act and CLT.

Citation: de Lange Z, Rijken DC, Hoekstra T, Conradie KR, Jerling JC, et al. (2013) In Black South Africans from Rural and Urban Communities, the 4G/5G PAI-1 Polymorphism Influences PAI-1 Activity, but Not Plasma Clot Lysis Time. PLoS ONE 8(12): e83151. doi:10.1371/journal.pone.0083151

Editor: Hugo ten Cate, Maastricht University Medical Center, The Netherlands

Received August 1, 2013; Accepted October 30, 2013; Published December 30, 2013

Copyright: © 2013 de Lange et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by SANPAD (South Africa - Netherlands Research Programme on Alternatives in Development); South African National Research Foundation (NRF GUN numbers 2069139, FA2006040700010 and FA200604100003. Any opinion, finding and conclusion or recommendation expressed in this material is that of the author(s) and the NRF does not accept any liability in this regard); the South African Medical Research Council; the North-West University, Potchefstroom, South Africa; and the PHRI (Population Health Research Institute), ON, Canada. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: marliien.pieters1@nwu.ac.za

Introduction

The prevalence of cardiovascular disease (CVD) has increased significantly in developing countries, and will continue to do so in the future [1]. The increase in morbidity and mortality from CVD is also seen in the black population of South Africa [2,3], particularly as a result of urbanisation, which is the change in lifestyle patterns brought about by the on-going migration from rural to urban settings. One of the factors that have repeatedly been shown to be associated with an increased risk of CVD is increased levels of plasminogen activator inhibitor type-1 (PAI-1) [4,5]. PAI-1 can contribute to the development of CVD through several mechanisms, including influencing plaque formation as well as being a major inhibitor of blood clot lysis [6,7]. The speed with which the body can lyse clots, often reported as lysis time, has been linked to CVD [9]. This reflects an individual’s fibrinolytic potential and can be measured with the use of global fibrinolytic assays. PAI-1 antigen (PAI-1ag) levels have been found to explain a large portion (24%) of the variance in clot lysis time (CLT) in a white population [9], while PAI-1 activity (PAI-1 act) explained 27% of CLT variance in the black African PURE population [10]. PAI-1 levels have previously been shown to be consistently lower in black African and African American populations than in populations of European decent [11–16]. However, as a result of urbanisation and the increased prevalence of various CVD risk factors associated with it, PAI-1 levels in urbanised black South Africans are increasing [16,17]. Environmental factors known to influence PAI-1 differ significantly between rural and urban settings [17]. PAI-1 levels are influenced by both environmental and genetic factors. There is, however, not much information available in the literature regarding the genetic determinants of PAI-1 levels, especially in black Africans. One of the most extensively studied genetic polymorphisms known to influence PAI-1 levels is the 4G/5G polymorphism [18,19]. This is a single base-pair insertion/deletion polymorphism in the promoter area of the PAI-1 gene [18,20]. The results of a recent large genome-wide association study (GWAS) meta-analysis showed that a SNP (rs2227631),
considered a proxy SNP for the 4G/5G polymorphism, was strongly associated with PAI-1 levels [21]. High PAI-1 levels have been found in participants who are homozygous for the 4G allele, intermediate levels in heterozygous participants and low PAI-1 levels in 5G homozygotes [12,22,23]. The 4G/5G polymorphism is, furthermore, considered to be a response polymorphism. This implies that the difference in PAI-1 levels between 4G and 5G becomes more obvious in the presence of disease and/or environmental factors which stimulate PAI-1 expression [24]. A limited number of studies in African Americans showed a higher prevalence of the 5G allele than in whites [12,25]. Much less data is available for continental African populations. To date, only three small-scale studies have been performed in black African individuals, showing an even higher prevalence of the 5G allele than in African Americans [15,26,27].

The aim of this study was therefore to identify genetic polymorphisms in the promoter area of the PAI-1 gene and to determine their effect on PAI-1 act. In addition we investigated whether these possible differences in PAI-1 act levels translated into altered global fibrinolytic potential (plasma clot lysis time). Owing to large differences in environmental factors between the rural and urban setting, we also aimed to investigate the effect of gene-environment interactions (e.g., BMI, blood lipids) on PAI-1 act and CLT and whether these interactions were influenced by urbanisation which can be viewed as a specific combination/grouping of environmental factors.

Methods
Study population
Participants were recruited to take part in the South African arm of the international PURE study. This is a large-scale cohort study that tracks changing lifestyles, risk factors and chronic disease, using periodic standardised data collection in rural and urban areas of 17 countries in transition over 12 years [28,29]. The data reported here are from the baseline data of 2010 randomly selected participants from well-established rural and urban study sites in the North West Province of South Africa, collected over a twelve-week period in 2005. Details regarding the selection process and randomisation are reported elsewhere [10,17]. In short, apparently healthy black South African men and women between the ages of 33 and 65 years were eligible to participate. Use of chronic medication for non-communicable diseases and/or any self-reported acute illness were bases for exclusion. Equal numbers of rural and urban participants were included.

Ethics statement
The Ethics Committee of the North-West University, South Africa, approved this study. The study procedure was explained to participants in their home language, after which participants signed informed consent forms and the study commenced. All data were treated confidentially and all analyses were performed with coded data.

Blood collection and laboratory analysis
Fasting blood samples were collected between 08:00 and 11:00. For the analysis of the lipid profile, blood was collected in tubes without anticoagulant - in EDTA tubes for the determination of glycosylated haemoglobin (HbA1c) and total homocysteine, and in fluoride tubes for glucose determination. For the determination of PAI-1 act, fibrinogen concentration, fibrinogen gamma prime, plasma fibrinolytic potential and for DNA isolation, blood was collected in citrate tubes. Samples were centrifuged at 2000 x g for 15 minutes at 10°C within 30 minutes of collection. Aliquots were frozen on dry ice, stored in the field at −18°C and then, after 2–4 days, at −82°C until analysis.

Methods for the measurement of fibrinogen, lipids, HbA1c, total homocysteine and plasma glucose have been described previously [17]. PAI-1 act was measured using an indirect enzymatic method [Spectrolyze PAI-1, Trinity Biotech, Bray, Ireland]. A modified Clauss method (Multifibrin U-test, Dade Behring, Deerfield, IL, USA) on the Dade Behring BCS coagulation analyser was used to determine fibrinogen concentrations. Fibrinogen gamma prime was determined with an enzyme-linked immunosorbent assay (ELISA) method using a 2G2H11 mouse monoclonal coating antibody against the human gamma prime sequence from Santa Cruz Biotechnology (Santa Cruz, USA) for antigen capture and a goat polyclonal HRP-conjugated antibody against human fibrinogen from Abcam for development (Antibody 7539, Cambridge, USA) [30]. Plasma fibrinolytic potential using tissue-factor-induced plasma clots, lysed by exogenous tPA, was measured using the method of Lismay et al. [9], validated by Talens et al. [31] with slightly modified tissue factor and tPA concentrations in order to obtain comparable CLTs of about 60 min (intra-assay CV = 3.6%, between plate CV = 4.5%). Final concentrations were tissue factor (125 x diluted – an estimated final concentration of 39 pM [92]; Dade Innovin, Siemens Healthcare Diagnostics Inc., Marburg, Germany); CaCl2 (17 mmol/l); tPA (100 ng/ml; Actilyse, Boehringer Ingelheim, Ingelheim, Germany) and phospholipid vesicles (10 μmol/l; Rossit, Molndal, Sweden). CLT was defined as the time from the midpoint of the transition of clear to maximum turbidity, which is representative of clot formation, to the midpoint in transition from maximum turbidity to clear, which represents the lysis of the clot [9]. CLT and PAI-1 act could be determined for only 1802 and 1913 participants respectively, owing to inadequate sample volume and/or haemolysis of some samples. Baseline characteristics of these participants did not differ from those of the total group.

PAI-1 promoter area sequencing and genotyping
Three overlapping fragments covering the promoter area from nucleotide position 100 768 248 – 100 770 521 (according to the NCBI database NP_000593.1) were sequenced in a subgroup of 25 randomly chosen participants and used as a representative group of the study population. PCR products were purified and bi-directionally sequenced using the BigDye® Terminator v3.1 Cycle Sequencing kit (AppliedBiosystems, CA, USA) (Table S1). After this, capillary electrophoresis was performed by the Central Analytical Facility of the Stellenbosch University on a 3130xl Genetic Analyser (AppliedBiosystems) [33]. Sequences were aligned to a reference sequence (NT_007933.15) using BioEdit v7 and were manually checked for known and novel polymorphisms. Seventeen polymorphisms were observed (Table S2). After linkage disequilibrium analysis and exclusion of two SNPs in linkage with the 4G/5G polymorphism, the polymorphisms with the highest frequencies, the 4G/5G polymorphism (rs1799889), located at chromosome position 100 769 970, and two SNPs located next to each other, at chromosome position 100 768 428 and 100 768 429 (rs36228614) were selected for analysis in the total PURE population. The novel polymorphism at position 100 768 428 will be referred to as C428T, and the polymorphism next to it as G429A. This SNP has been previously reported, but no data exists in the literature for this SNP. The 25 participants from the subgroup were used as controls in further analysis.
The 4G/5G-polymorphism was genotyped using TaqMan-based assays, as previously described [34], using the BioRad IQ5 real-time polymerase chain reaction (PCR) machine (Bio-Rad, Hercules, USA). A final concentration of 1.2 μM of each primer was used and 0.4 μM of each probe at an annealing temperature of 63°C.

The double nucleotide polymorphism C428T-G429A was genotyped by using a TaqMan-based assay using the BioRad IQ5 real-time PCR machine. A multiplex real-time PCR reaction was then performed, using four different probes (Table S3). A final concentration of 0.4 μM of each primer and 0.2 μM of each probe was used. The annealing temperature for the reaction was optimised at 62.4°C. Sequences are available in Table S3.

Statistical analysis
Data were analysed with the computer software package Statistica (Staats Inc., Tulsa Oklahoma, USA). A p-value of 0.05 or less was regarded as statistically significant. Normally distributed data are reported as means (95% confidence interval or standard deviation). Data that were not normally distributed were log-transformed to improve normality and are reported as geometric mean (95% confidence interval). Owing to the large number of participants who had PAI-1 values of 0 as calculated from the standard curve of the assay, a value of 1 was added to all PAI-1 values before log transformation. This was subtracted again when reporting the data. Forward stepwise multiple regression was used to determine the contribution of various traditional CVD risk factors to PAI-1 variance. Mean differences with 95%CI and t-tests were used when comparing differences between two groups. One-way analysis of variance (ANOVA) and Tukey’s Honest Significant Difference post-hoc tests were used when comparing more than two groups. To investigate possible gene-environment interactions between PAI-1 genotypes and other factors and whether these interactions differed for rural and urban groups, interaction terms were entered into an analysis of co-variance (ANCOVA) with full factorial analysis. In addition, regression slopes were compared. For these interaction analyses, if sample sizes were too small, the homoygous mutant genotype groups were combined with the heterozygous group, i.e. 5G/5G compared with the 4G/X allele group, CC compared with the T/X group, and GG compared with the A/X group. Analyses of the C428T and G429A SNPs combined did not yield different results from when analysed separately (data not reported).

Results
PAI-1 and CLT across PAI-1 genotypes
General population characteristics of the South African PURE population have been described previously [10,17] and are included in Table S4. The distribution of all three genotype classes of each of the polymorphisms investigated adhered to the assumptions of Hardy Weinberg equilibrium. For the three polymorphisms we investigated, the linkage disequilibrium in the total study population between polymorphisms 4G/5G and C428T was: D’ 1.0, r² = 0.007; between 4G/5G and G429A D’ 0.72, r² = 0.011; and between C428T and G429A D’ 0.72, r² = 0.003. Because of the low r², we report results for the three SNPs separately. The allele frequencies of the three polymorphisms are presented in Table 1.

The geometric mean PAI-1 level of the South African PURE population was 3.55±1.60 (median 4.26 (1.27–7.92)) U/ml. Data for PAI-1 levels and CLT across genotypes are presented for the total population as well as for the urban and rural participants separately in Table 1. PAI-1 levels for the total population and for the urban subgroup differed significantly across the 4G/5G genotypes, where 5G homozygous participants presented with the lowest PAI-1 levels and 4G homozygous participants with the highest PAI-1 levels, while heterozygous participants had intermediate PAI-1 levels. In the rural group, PAI-1 was higher in the 4G/4G group only. BMI, however, differed across genotypes in the rural group (5G/5G: 22.6, 4G/5G: 21.3 and 4G/4G: 23.4, 4G/5G: 23.3 and 4G/4G: 25.5 kg/m² p = 0.83). Because of the known relationship between BMI and PAI-1 levels, we adjusted for BMI. After this adjustment, differences between PAI-1 levels across the genotypes remained in the urban subgroup but had only borderline significance in the rural group (p = 0.06). No significant differences in clot lysis times between the genotype subclasses of the 4G/5G polymorphism were detected in the total population (p = 0.12) or in the urban group (p = 0.40). However, in the rural participants, those who had the homozygous 4G genotype had borderline significantly longer CLT than the homozygous 5G and heterozygous genotypes (63.1 vs 57.0 and 56.6 minutes, p = 0.04). Again after the adjustment for BMI, this significance disappeared.

Because the homozygous mutant genotype group (TT) of C428T was too small (n = 2) to include in further analysis as a separate group, it was combined with the CT heterozygous group. Neither PAI-1 levels nor clot lysis times differed significantly between the homozygous C or T-allele group of C428T for the total population or for the rural and urban subgroups.

For the G429A SNP, the homozygous mutant (AA genotype) (n = 27) was also combined with the GA genotype for further analysis. No significant differences in PAI-1 levels or clot lysis times were observed between the GG and A-allele genotypes in the total, rural or urban groups, except for PAI-1 levels, which was higher in the GG-genotype than in the group carrying the A-allele in the urban subgroup.

Associations of cardiovascular disease risk factors with PAI-1
The contributions of various traditional CVD risk factors to PAI-1 variance in this population were determined using forward stepwise multiple regression. Risk factors included in the regression model were: age, sex, waist circumference, triglycerides, HDL-cholesterol, LDL-cholesterol, HbA1c, total homocysteine, fibrinogen, fibrinogen gamma prime, blood pressure, smoking and 4G/5G genotype. These factors explained 24% of the variance in PAI-1 in this population. Waist circumference explained most of the variance with 12.5%, sex, triglyceride and fibrinogen concentration explained 5%, 4% and 1% respectively, while the 4G/5G polymorphism, fibrinogen gamma prime, blood pressure, smoking and HDL-cholesterol each explained less than 1%. Age, LDL-cholesterol, HbA1c and tHcy did not enter the model. Associations of CLT and CVD risk factors have been reported in De Lange et al. [10].

Gene-environment interactions
Next we investigated the possible of gene-environment interactions on PAI-1 levels and CLT using the CVD risk factors that were significantly associated with PAI-1 and CLT. Results are presented for the interactions found for the 4G/5G polymorphism with PAI-1 and CLT. Results reporting interactions of the C428T and G429A polymorphisms with PAI-1 and CLT are available in Supporting Information S1 and Table S3.

When the participants were divided according to BMI, PAI-1 levels differed across the genotypes of the 4G/5G polymorphism in
individuals in the normal, overweight and obese BMI range, but not in underweight participants (BMI <18.5 kg/m²), and in participants with central adiposity but not in participants with normal waist circumference (Table 2). CLT did not differ across the genotypes in any of the BMI categories, but tended to be longer in the 4G allele carriers in participants with central adiposity.

Furthermore, there was no difference in the genotypes in any of the BMI categories, but tended to be longer in the 4G allele carriers in participants with central obesity.

Distribution of the 4G/5G genotypes were similar in individuals harbouring the respective mutant alleles, while no rural-urban differences were present in participants homozygous for the respective wild type alleles.

The genotypes of the C428T and G429A polymorphisms also had significant interactions with various CVD risk factors in determining PAI-1act and CLT (Table S5). In general it seems that, for both polymorphisms, differences in gene-environment interactions were observed between rural and urban participants in individuals harbouring the respective mutant alleles, while no rural-urban differences were present in participants homozygous for the respective wild type alleles.

Discussion

This study provides the first population-based data for genotype frequencies of the 4G/5G polymorphism in a large black African population. To date there have been only three small-scale studies and our data indicate an even higher prevalence of the 5G allele than previously reported for African Americans. In addition we aimed to identify other factors contributing to PAI-1act variance in Africans by identifying other polymorphisms in the PAI-1 promoter area.

Table 1. PAI-1act levels and clot lysis time of PAI-1 promoter area polymorphisms.

| Polymorphism | Allele Freq. | N (%) | PAI-1act (U/ml) | CLT (min) |
|--------------|-------------|------|----------------|-----------|
|              |             |      | Total group | Urban | Rural | Total group | Urban | Rural |
| 4G/5G        | 5G/5G       | 1304 | 72.5        | 3.35 (3.13-3.58)* | 2.90 (2.64-3.18)* | 5.07 (5.46-5.76) | 7.51 (5.61-5.81) | 5.70 (5.62-5.78)* |
|              | 5G: 0.85    |      | (n = 1302) | (n = 602) | (n = 700) | (n = 1223) | (n = 557) | (n = 666) |
| 4G/5G        | 4G (24.9)   | 448  |             | 3.90 (3.48-4.37)* | 2.95 (2.47-3.50) | 5.75 (5.48-5.86) | 5.83 (5.79-5.99) | 5.66 (5.51-5.81) |
|              |             |      | (n = 446) | (n = 243) | (n = 203) | (n = 426) | (n = 229) | (n = 197) |
| 4G/4G        | 4G: 0.15    | 47   |             | 5.87 (4.10-8.25)* | 5.74 (3.46-9.18)* | 6.05 (5.58-6.52) | 5.85 (5.91-6.54) | 63.1 (56.3-69.8)* |
|              |             |      | (n = 47) | (n = 26) | (n = 21) | (n = 43) | (n = 24) | (n = 19) |
| C428T        | CC          | 0.96 | 1743 (92.3) | 4.25 (3.82-4.60) | 3.02 (2.78-3.28) | 5.73 (5.67-5.78) | 5.75 (5.78-5.83) | 5.71 (5.63-5.78) |
|              |             |      | (n = 1739) | (n = 861) | (n = 878) | (n = 1640) | (n = 801) | (n = 839) |
| G429A        | GG          | 0.90 | 1528 (80.9) | 4.43 (4.07-4.81) | 2.92 (2.67-3.19) | 5.73 (5.67-5.79) | 5.76 (5.67-5.84) | 5.70 (5.62-5.78) |
|              |             |      | (n = 1524) | (n = 760) | (n = 764) | (n = 1443) | (n = 713) | (n = 730) |
|             | GA /AA      | 0.10 | 360 (19.1)  | 3.44 (2.81-4.17) | 3.15 (2.66-3.71) | 5.73 (5.61-5.84) | 5.74 (5.44-5.93) | 5.72 (5.57-5.86) |
|              |             |      | (n = 359) | (n = 163) | (n = 196) | (n = 333) | (n = 145) | (n = 188) |

PAI-1act data reported as geometric means (95% CI), normally distributed data (CLT) reported as mean (95% CI). PAI-1act: Plasminogen activator inhibitor type-1 activity; CLT: clot lysis time.

**p-values after adjustment for BMI; ** p-value reported for CC vs CT and TT groups combined for C428T, and GG vs GA and AA groups combined for G429A because of small sample size in homozygous mutant groups.

doi:10.1371/journal.pone.0083151.t001

5G/5G homozygotes. Urbanisation did not influence these gene-environment interactions.

The genotypes of the C428T and G429A polymorphisms also had significant interactions with various CVD risk factors in determining PAI-1act and CLT (Table S5). In general it seems that, for both polymorphisms, differences in gene-environment interactions were observed between rural and urban participants in individuals harbouring the respective mutant alleles, while no rural-urban differences were present in participants homozygous for the respective wild type alleles.
Influence of 4G/5G Polymorphism on PAI-1 and CLT

**Table 2.** PAI-1<sub>act</sub> and CLT across BMI and waist circumference categories for 5G/5G participants and those harbouring the 4G genotype

| PAI-1<sub>act</sub> (U/ml) | CLT (minutes) |
|--------------------------|--------------|
| N | 5G/5G | 4G-allele | Mean difference (95% CI) | 5G/5G | 4G-allele | Mean difference (95% CI) |
| Mean* (95% CI) | Mean* (95% CI) | Mean (95% CI) | Mean (95% CI) |
| BMI (kg/m<sup>2</sup>): | | | | | | |
| <18.5 | 319 | 1.89 (1.56-2.26) | 1.64 (1.18-2.21) | 0.24 (-0.14-0.62) | 50.7 (49.2-52.2) | 50.9 (48.6-53.2) | 0.24 (-2.48-2.95) |
| 18.5-24.9 | 731 | 2.65 (2.37-2.94) | 3.39 (3.03-4.22) | 0.94 (0.69-1.18) | 54.9 (54.0-55.8) | 56.1 (54.5-57.7) | 1.22 (-0.59-3.02) |
| 25-29.9 | 298 | 4.83 (4.23-5.49) | 6.22 (4.95-7.75) | 1.39 (1.05-1.74) | 60.7 (59.4-61.9) | 61.6 (58.8-64.4) | 0.92 (-2.11-3.95) |
| ≥30 | 353 | 5.52 (4.87-6.25) | 7.55 (6.12-9.28) | 2.03 (1.69-2.37) | 64.2 (63.1-65.3) | 65.1 (63.0-67.3) | 0.91 (-1.52-3.33) |
| Waist circumference: | | | | | | |
| Normal WC | 1422 | 2.89 (2.67-3.12) | 3.14 (2.76-3.55) | 0.25 (-0.07-0.43) | 55.3 (54.6-56.0) | 55.3 (54.2-56.5) | 0.06 (-1.24-1.36) |
| Centrally obese | 356 | 5.59 (5.22-6.62) | 9.29 (7.78-11.1) | 3.41 (3.12-3.70) | 64.4 (63.3-65.5) | 66.7 (64.3-69.2) | 2.33 (-0.33-4.99) |

*Geometric mean; PAI-1<sub>act</sub>: plasminogen activator inhibitor type-1 activity; CLT: clot lysis time; BMI: body mass index; WC: Waist circumference; Normal WC: <80cm for women and <94cm for men; Central obesity, ≥80cm for women and ≥94cm for men.

doi:10.1371/journal.pone.0083151.t002

**Table 3.** PAI-1<sub>act</sub>, plasminogen activator inhibitor type-1 activity; BMI: body mass index; CLT: clot lysis time.

| Interaction | Interaction p-value* | N | Slope (95% CI) | N | Slope (95% CI) |
|-------------|----------------------|---|----------------|---|----------------|
| PAI-1<sub>act</sub> | | | | | |
| Waist circumference (cm) | 0.001 | 1289 | 1.89 (1.57-2.21) | 489 | 2.92 (2.42-3.43) |
| BMI (kg/m<sup>2</sup>) | 0.006 | 1241 | 1.15 (0.96-1.34) | 460 | 1.66 (1.35-1.97) |
| Triglycerides (mmol/l) | 0.04 | 1259 | 0.56 (0.46-0.66) | 481 | 0.78 (0.60-0.95) |
| CLT: | | | | | |
| Fibrinogen (g/L) | 0.005 | 1149 | 2.69 (1.55-3.82) | 425 | 5.94 (3.83-8.06) |
| Fibrinogen gamma prime (g/L) | 0.04 | 1173 | 6.78 (5.69-7.88) | 444 | 9.04 (7.06-11.0) |

*P-values indicate significance of the interaction term of the 4G/5G genotype and environmental factor in an ANCOVA.

PAI-1<sub>act</sub> and CLT across PAI-1 genotypes

In this large black African population we found a high prevalence of the 5G/5G genotype (72.5%) of the 4G/5G polymorphism. These results agree with the results of two small-scale studies conducted in black South African participants, in which the 5G homozygous genotype was present in 76% and 77.6% of the populations in comparison with 36% and 19.3% in white South Africans [15,26]. The 5G allele frequency (0.85) was higher than that reported for African American, (0.74 and 0.72), and white populations (0.38 and 0.28) [12,25].

In agreement with results from other studies, we also found PAI-1<sub>act</sub> levels of the 4G homozygous genotype to be higher than those of the 4G/5G heterozygous and 5G homozygous genotypes, with the 4G/5G genotype group presenting with intermediate PAI-1<sub>act</sub> levels of the 4G homozygous and 5G homozygous genotypes, with white populations (0.38 and 0.28) [12,25].

In agreement with results from other studies, we also found PAI-1<sub>act</sub> levels of the 4G homozygous genotype to be higher than those of the 4G/5G heterozygous and 5G homozygous genotypes, with the 4G/5G genotype group presenting with intermediate PAI-1<sub>act</sub> levels in the overall population [12,22,23]. Interestingly, this difference in PAI-1<sub>act</sub> levels between genotypes of the 4G/5G polymorphism was much more pronounced in the urban than in the rural subgroup, suggesting that urbanisation-dependent stimuli might modulate gene expression through an interaction with the 4G/5G polymorphism. Future studies identifying these stimuli are warranted to confirm this hypothesis. Despite increased PAI-1<sub>act</sub> levels in both the rural and urban subgroups in the 4G/4G genotype, this change did not translate to longer CLTs.

Neither PAI-1<sub>act</sub> nor CLT differed across the novel C428T or C429A genotypes except in the urban subgroup, where homozygous wildtype participants had significantly higher PAI-1<sub>act</sub> levels than the A-allele group. Although the G429A polymorphism has been previously identified, no information is available in the literature regarding its effect on PAI-1 levels. A possible reason for the apparent lack of effect of these two SNPs may be that the SNPs were not present within a known transcription factor binding site (as determined with the UCSC genome browser using the TFBS conserved and ENCODE regulation tracks).

Associations of cardiovascular disease risk factors with PAI-1<sub>act</sub>

The 4G/5G polymorphism explained less than one percent of the variance of PAI-1<sub>act</sub> in this population. The main contributor to PAI-1<sub>act</sub> variance in this population was waist circumference, followed by sex and triglyceride concentration. This is in agreement with Verschuur et al. [35], who found obesity to be a more important determinant of PAI-1 levels than genetic variation in the PAI-1 promoter area. It is also possible, however, that PAI-1 levels can be influenced by polymorphisms outside the PAI-1 gene. Huang et al. [21], for example recently found SNPs in the ARNTL and the PPARG genes to have genome-wide significant association with circulating PAI-1 levels.
Gene-environment interactions - 4G/5G polymorphism

The relationship between PAI-1 levels, the 4G/5G genotype and BMI, although extensively studied, remains controversial. Genotype-specific differences in PAI-1 act levels were present in all BMI ranges in our study population, except for BMI <18.8 kg/m², whereas in white populations, they have sometimes been observed in obese individuals only [36–38], while in other studies [35] they have appeared in lean individuals only. In agreement with results from Sartori et al. [36], these differences were also present in individuals with central obesity but not in those with a normal waist circumference. We additionally found significant interactions of the 4G/5G genotypes with waist circumference and BMI in determining PAI-1 act levels in this apparently healthy population, with PAI-1 act increasing more rapidly with increasing BMI and WC in the 4G allele group. These results are in agreement with McCormack et al. [39], who investigated these associations in Pima Indians. Ossei-Gerning et al. [23], however, found the association between BMI and PAI-1 to be stronger in the 5G/5G genotype in a group of 453 white patients with a history of myocardial infarction. In vitro studies aiming at elucidating possible mechanisms for this interaction, found no effect of genotype on promoter activity in HepG2 or BEAC cells [35], nor did it influence the adipose secretion rate of PAI-1 [40].

The 4G/5G polymorphism being a response polymorphism, with the 5G allele, as has been demonstrated for interleukin-1 [18] and VLDL, it could at least in part explain the observed gene-environment interactions. The enhanced transcription of PAI-1 could consequently result in prolonged CLT. Additional research is required, however, to test this hypothesis.

C428T and G429A polymorphisms

Despite there being no direct relationship between these polymorphisms and PAI-1 act and CLT, we did find evidence that the association of other environmental factors with PAI-1 act and CLT was influenced by these genotypes. Additionally, many, but not all, of the gene-environment interactions differed consistently between rural and urban participants in subjects harbouring the mutant alleles, but not in subjects harbouring the most common genotype. These data suggest that significant differences in environmental factors in urban and rural living conditions could potentially influence phenotypic expression of the investigated SNPs in subjects harbouring the mutant variants and that these individuals may be more sensitive towards environmental factors than individuals harbouring the respective common genotypes.

In conclusion, this black African population had a high prevalence of the 5G allele (0.85). The 4G/5G polymorphism significantly affected PAI-1 act but not CLT. The polymorphism contributed, however, to less than 1% in the PAI-1 act variance. Obesity had a much more pronounced effect on PAI-1 act than the measured polymorphisms. The C428T and G429A SNPs had no direct association with either PAI-1 act or CLT. There were significant gene-environment interactions for all three polymorphisms investigated in determining PAI-1 act and CLT. Urbanisation significantly affected the phenotypic expression of the 4G/5G polymorphism, with PAI-1 act showing larger differences across the 4G/5G genotypes in the urban community than in the rural community. Urbanisation additionally influenced gene-environment interactions, with differences between rural and urban participants observed particularly in participants harbouring the minor alleles of the C428T and G429 polymorphisms. From these results it seems clear that environmental factors and combinations thereof, such as specific combinations present in a rural or urban environment, significantly influence phenotypic expression of genes. This should be taken into consideration when developing treatment modalities addressing CVD risk factors such as PAI-1 and hypofibrinolysis in communities in transition.

Supporting Information

Table S1 Primers used to sequence PAI-1 promoter area.

(DOC)
Table S2 Polymorphisms found in the subgroup of n = 25 of the PURE population. * rs numbers not available.

| Polymorphism                      | Description                                                                 |
|-----------------------------------|-----------------------------------------------------------------------------|
| PAI-1 (4G/5G)                     | Genotype associated with myocardial infarction                               |
| *rs4135857 (C428T)                | Promoter-related SNP that responds differently to interleukin-1 in HepG2 cells |
| *rs1515372 (G429A)                | Promoter-related SNP that responds differently to interleukin-1 in HepG2 cells |

References

1. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K (2007) The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 370:1929–1938.
2. Amira C, Nyintyanye L, Wilkinson D, Stewart S, Becker A, et al. (2006) Emerging epidemic of cardiovascular disease among urban Africans: Acute coronary syndrome at Baragwanath hospital, Soweto, SA. Heart J 3:17–22.
3. Stewart S, Carrington M, Pretorius S, Methusi P, Sliwa K (2011) Standing at the crossroads between and historically prevalent heart disease: effects of migration and socio-economic factors in the Heart of Soweto cohort study. Eur Heart J 32:492–499.
4. Hamsten A, De Faire U, Wallin G, Dahlén G, Szamosi A, et al. (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 330:3–9.
5. Kohler HP, Grant PJ (2000) Plasminogen-activator inhibitor type-1 and coronary artery disease. N Engl J Med 342:1792–1801.
6. Sobel BE, Taatjes DJ, Scheneider DJ (2003) Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 23:1979–1989.
7. Dallas C, Loskutoff DJ (2005) Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93:631–640.
8. Lieman T, De Groot PG, Meijers J, Rosendaal F (2005) Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 105:1102–1105.
9. Meltzer ME, Lieman T, De Groot PG, Meijers JC, Te Cessie S, et al. (2010) Venous thrombosis risk associated with plasma fibrinogen is explained by elevated plasma levels of TAFI and PAI-1. Blood 116:113–121.
10. De Lange Z, Pieters M, Jerling JC, Kruger A, Rijken DC (2012) Plasma clot lysis time and its association with cardiovascular risk factors in black Africans. PLOS One 7:1–8 e48831.
11. Jerling J, Vosser H, Oosthuizen W, Silvis N, Venter CS (1994) Differences in plasminogen activator inhibitor 1 activity between blacks and whites may be diet related. Arterioscler Thromb Vasc Biol 24:364–368.
12. Festa A, D’Agostino R, Rich SS, Jenny NS, Tracy RP, et al. (2003) Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites. Circulation 107:2422–2427.
13. Latsey PL, Cushman M, Steffen LM, Green D, Barr RG, et al. (2006) Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J Thromb Haemost 2006; 4:2629–2635.
14. Greselin A, Pieters M, Hoekstra T, Oosthuizen W, Schatte AE (2007) Differences in the association of PAI-1 activity with the metabolic syndrome between African and Caucasian women. Nutr Metab Cardiovasc Dis 17:499–507.
15. Naran NH, Chetty N, Gowerth NJ (2008) The influence of metabolic syndrome components on plasma PAI-1 concentrations is modulated by the PAI-1 4G/5G genotype and ethnicity. Atherosclerosis 196:155–163.
16. Pieters M, Vosser HH (2008) Nutrition and hemostasis: a focus on urbanization in South Africa. Mol Nutr Food Res 52:164–172.
17. Pieters M, De Maat MMP, Jerling JC, Hoekstra T, Kruger A (2011) Fibrinogen and its role in CVD risk in black South Africans – effect of urbanisation. Thromb Haemost 106:448–456.
18. Dawson S, Wiman B, Hamsten A, Green F, Humphries S, et al. (1995) The two allelic sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268:10739–10745.
19. Nordt TK, Loehmann J, Bode C (2001) Regulation of PAI-1 expression by genetic polymorphisms – impact on atherosclerosis. Thromb Res 103:1–5.
20. Eriksson P, Kallin B, van’t Hoof FM, Våneholm P, Hamsten A (1995) Allelic specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851–1855.
21. Huang J, Sabater-Lleal M, Asselbergs FW, Trezuet D, Shin SY, et al. (2012) Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. Blood 120:4873–4881.
22. Ye S, Green F, Scarabin P, Nicaud V, Bara L, et al. (1995) The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Erasme CasTemoins de l’infarctus du Myocarde. Thromb Haemost 74:837–841.
23. Osei-Gerning N, Mansfield MW, Sickland MH, Wilson J, Grant PJ (1997) Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 17:33–37.
24. Hoekstra T, Geleijnse JM, Schouten EG, Kluit P (2004) Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 91:661–672.
25. Lanfar DA, Marsh S, Crespi S, Shannon WD, Sperutas JA, et al. (2004) Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans. J Am Col Cardiol 44:163–167.
26. Pegoraro RJ, Hira B, Rom I, Moodley J (2003) Plasminogen activator inhibitor type 1 (PAI1) and platelet glycoprotein IIb/IIIa (PGIIb/IIIa) polymorphisms in Black South Africans with pre- eclampsia. Acta Obstet Gynecol Scand 82:313–317.
27. Schoenhardt JA, Asselbergs FW, Poku KA, Stocchi SA, Gordon S, et al. (2008) Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population. Hum Genet 124:479–489.
30. Uitte de Willige S, de Visser MCH, Houwing-Duistermaat JJ, Rosendaal FR, Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, et al. (2011) Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378:1231–1243.

31. Talens S, Malfliet JJMC, Rudez G, Spronk HM, Janssen NA, et al. (2012) Biological variation in tPA-induced plasma clot lysis time. Thromb Haemost 108:640–646.

32. Duckers C, Simoni P, Sipioja L, Radu C, Dabrulli P, et al. (2010) Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. Blood 115:879–886.

33. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci 74:5463–5467.

34. Tjärlund A, Andersson M, Jood K, Ladenvall P, Jern C (2003) Rapid genotyping of haemostatic gene polymorphisms using the 5' nucleotide assay. Thromb Haemost 89:936–942.

35. Verschuur M, Jellema A, Bladbjerg EM, Fekers EJ, Mensink RP, et al. (2005) The plasminogen activator inhibitor-1 (PAI-1) promoter haplotype is related to PAI-1 plasma concentrations in lean individuals. Atherosclerosis 181:275–284.

36. Björnorp P (1990) Portal adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 10:493–496.

37. Vague J (1956) The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric acid disease. Am J Clin Nutr 1:20–34.

38. Sartori MT, Vettor R, De Pergola G, De Mitrio, Saggiorato G, et al. (2001) Role of the 4G/5G polymorphism of PAI-1 gene promoter on PAI-1 gene expression and adipocyte differentiation. Clin Appl Thromb Haemost 14:435–446.

39. Gardemann A, Löhre J, Katz N, Tillmanns H, Hehrlein FW, et al. (1999) The -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia 45:304–307.

40. Kinik ST, Olsbek N, Yace M, Yaacini AC, Verdi H, et al. (2008) PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children. Thromb Haemost 99:352–356.

41. McCormack LJ, Nagi DK, Stickland MH, Mansfield MW, Mohamed-Ali V, et al. (1996) Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. Diabetologia 39:1512–1518.

42. Van Harnelen V, Wahrenberg H, Eriksson P, Arner P (2000) Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue. Thromb Haemost 83:304–308.

43. Mansfield MW, Stickland MH, Grant PJ (1995) Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 74:492–747.

44. Van Harmelen V, Wahrenberg H, Eriksson P, Arner P (2000) Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue. Thromb Haemost 83:304–308.